Publications by authors named "Maria-Victoria Mateos"

100Publications

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.

J Clin Med 2020 Sep 27;9(10). Epub 2020 Sep 27.

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9103120DOI Listing
September 2020

Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.

Lancet Haematol 2020 08;7(8):e559

Levine Cancer Institute-Atrium Health, Charlotte, NC 28204, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30188-5DOI Listing
August 2020

Measurable residual disease in multiple myeloma: ready for clinical practice?

J Hematol Oncol 2020 06 22;13(1):82. Epub 2020 Jun 22.

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00911-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310444PMC
June 2020

Is there a role for new drugs with alkylating properties in multiple myeloma?

Lancet Haematol 2020 May 23;7(5):e357-e359. Epub 2020 Mar 23.

University Hospital of Salamanca, Instituto Biosanitario de Salamanca, Cancer Research Center, Salamanca 37007, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30073-9DOI Listing
May 2020

FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.

J Cell Mol Med 2020 Apr 6;24(7):4171-4182. Epub 2020 Mar 6.

Haematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.15078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171423PMC
April 2020

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.

BMC Cancer 2020 Mar 3;20(1):170. Epub 2020 Mar 3.

Seragnoli Institute of Haematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-6596-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055060PMC
March 2020

Improving the conditioning regimen in multiple myeloma.

Lancet Haematol 2019 May 22;6(5):e234-e235. Epub 2019 Mar 22.

Hematology Department, University Hospital of Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30028-6DOI Listing
May 2019

Management of cardiovascular risk in patients with multiple myeloma.

Blood Cancer J 2019 02 26;9(3):26. Epub 2019 Feb 26.

Hematology Service, University Hospital Salamanca, Casa del Bedel, Cardenal Pla y Deniel, 22, Planta Baja, Salamanca, 37008, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0183-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391463PMC
February 2019

Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma.

Lancet Oncol 2019 01 14;20(1):5-6. Epub 2018 Dec 14.

Hematology Department, University Hospital of Salamanca, IBSAL, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30764-2DOI Listing
January 2019

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.

Br J Haematol 2019 06 22;185(5):981-984. Epub 2018 Nov 22.

Department of Haematology, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15680DOI Listing
June 2019

Timing of treatment of smoldering myeloma: early treatment.

Blood Adv 2018 11;2(21):3045-3049

Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018021220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234377PMC
November 2018

Unusual report of non-syndromic permanent unilateral mandibular canine agenesis.

Dent Res J (Isfahan) 2018 Sep-Oct;15(5):372-377

Department of Stomatology, School of Dentistry, University of Sevilla, Sevilla, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134732PMC
September 2018

Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.

Eur J Intern Med 2018 12 12;58:57-63. Epub 2018 Jun 12.

Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2018.05.029DOI Listing
December 2018

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

J Clin Oncol 2018 07 2;36(20):2035-2043. Epub 2018 Feb 2.

Meletios Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Katja Weisel, University Hospital of Tuebingen, Tuebingen, Germany; Niels W.C.J. van de Donk, VU Universiteit Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Karthik Ramasamy, Oxford University Hospital and NIHR BRC Blood Theme, Oxford; Matthew Streetly, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Barbara Gamberi, Arcispedale S. Maria Nuova, Reggio Emilia; Massimo Offidani, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona; Antonio Ardizzoia, Oncology Department, ASST Lecco, Lecco, Italy; Frank Bridoux, University Hospital and University of Poitiers, Poitiers, France; Javier de la Rubia, Hematology Service University Hospital Doctor Peset and Universidad Católica de Valencia "San Vicente Mártir," Valencia; Maria-Victoria Mateos, Instituto de Investigación Biomédica de Salamanca and University of Salamanca, Salamanca, Spain; Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, and Pamela Bacon, Celgene International, Boudry, Switzerland; and Yan Li, Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.1742DOI Listing
July 2018

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.

Crit Rev Oncol Hematol 2018 Jan 5;121:74-89. Epub 2017 Dec 5.

Department of Hematology, University of Nantes Health Centre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.11.016DOI Listing
January 2018

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

N Engl J Med 2018 02 12;378(6):518-528. Epub 2017 Dec 12.

From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center, Chicago (A.J.); Würzburg University Medical Center, Würzburg, Germany (S.K.); Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.); Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno, Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom; the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clínica de Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen Research and Development, Raritan, NJ (J.W., H.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714678DOI Listing
February 2018

Management of multiple myeloma in the newly diagnosed patient.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):498-507

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142596PMC
December 2017

When to initiate treatment in smoldering multiple myeloma.

Clin Adv Hematol Oncol 2017 Oct;15(10):751-753

Haematology Department, University Hospital of Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
October 2017